Revenue: As of FY2026 Q2, the actual value is USD 131.95 M, beating the estimate of USD 114.05 M.

EPS: As of FY2026 Q2, the actual value is USD 2.07, beating the estimate of USD 0.0225.

EBIT: As of FY2026 Q2, the actual value is USD 113.22 M.

CareDx, Inc. reported significant financial growth for the second quarter ended June 30, 2026, compared to the second quarter of 2025, with total revenue increasing by 52% year-over-year to $132 million from $87 million, primarily due to higher Testing Services revenue and expansion in Patient and Digital Solutions revenue.

Segment Revenue

• Testing Services Revenue: Testing Services revenue was $100 million in Q2 2026, marking a 61% year-over-year increase from $62 million in Q2 2025. Excluding prior period revenue, testing services revenue increased approximately 28% year-over-year.
• Patient and Digital Solutions Revenue: Patient and Digital Solutions revenue increased 50% year-over-year to $19 million in Q2 2026, from $13 million in Q2 2025.
• Lab Product Revenue: Lab Product revenue was $13 million in Q2 2026, an 8% increase year-over-year from $12 million in Q2 2025. The company completed the divestiture of its Lab Products business on June 30, 2026, indicating that future periods will not include these segment results.

Operational Metrics

• GAAP Net Income (Loss): CareDx, Inc. reported a GAAP net income of $111 million in Q2 2026, a substantial improvement from a GAAP net loss of -$9 million in Q2 2025. This figure includes a $113 million gain on the sale of the Lab Products business.
• Non-GAAP Net Income: Non-GAAP net income was $20 million in Q2 2026, compared to $6 million in Q2 2025.
• Adjusted EBITDA: Adjusted EBITDA reached $25 million in Q2 2026, significantly up from $5 million in Q2 2025. The adjusted EBITDA margin was 19% in Q2 2026, compared to 6% in Q2 2025.
• GAAP Gross Profit: GAAP gross profit was $96,982 thousand in Q2 2026, compared to $58,021 thousand in Q2 2025.
• GAAP Gross Margin: GAAP gross margin was 74% in Q2 2026, compared to 67% in Q2 2025.
• Non-GAAP Gross Profit: Non-GAAP gross profit was $97,969 thousand in Q2 2026, compared to $59,926 thousand in Q2 2025.
• Non-GAAP Gross Margin: Non-GAAP gross margin was 74% in Q2 2026, compared to 69% in Q2 2025.
• Operating Costs (GAAP):
  • Cost of Testing Services: Cost of Testing Services was $15,918 thousand in Q2 2026, compared to $15,406 thousand in Q2 2025.
  • Cost of Product: Cost of Product was $4,342 thousand in Q2 2026, compared to $4,981 thousand in Q2 2025.
  • Cost of Patient and Digital Solutions: Cost of Patient and Digital Solutions was $14,706 thousand in Q2 2026, compared to $8,271 thousand in Q2 2025.
  • Research and Development: Research and Development expenses were $22,376 thousand in Q2 2026, compared to $16,830 thousand in Q2 2025.
  • Sales and Marketing: Sales and Marketing expenses were $33,441 thousand in Q2 2026, compared to $24,279 thousand in Q2 2025.
  • General and Administrative: General and Administrative expenses were $40,908 thousand in Q2 2026, compared to $27,683 thousand in Q2 2025. This figure also included -$72,058 thousand in the non-GAAP reconciliation table for Q2 2026 due to the gain on sale of the lab products business.
• Income (Loss) from Operations: Income from operations was $113,223 thousand in Q2 2026, compared to a loss from operations of -$11,121 thousand in Q2 2025.

Cash Flow

• Cash Flow from Operations: Cash flow from operations was $30,606 thousand in Q2 2026, compared to $9,898 thousand in Q2 2025.
• Free Cash Flow (Non-GAAP): Free cash flow was $28,748 thousand in Q2 2026, compared to $8,891 thousand in Q2 2025.

Unique Metrics

• Testing Services Volume: Testing Services volume reached approximately 58,000 tests in Q2 2026, representing a 17% increase year-over-year.
• Average Revenue Per Test: The average revenue per test was approximately $1,720 in Q2 2026, which includes $16 million in prior period revenue.
• Gain on Sale of Lab Products Business: A gain of $113 million was recognized from the sale of the Lab Products business, included in GAAP operating income but excluded from non-GAAP operating income.

Outlook / Guidance

For the full year 2026, CareDx, Inc. raised its revenue guidance to a range of $490 million to $500 million, up from the previously disclosed range of $447 million to $465 million. The company also increased its full-year 2026 adjusted EBITDA guidance to a range of $66 million to $78 million, compared to its prior guidance of $43 million to $57 million. The company expects continued profitable growth and anticipates integrating Naveris and launching into cell therapy.